Corixa Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Seattle WA United States (1994)
Status: Acquired by GlaxoSmithKline (2005)

Organization Overview

First Clinical Trial
1998
NCT00022958
First Marketed Drug
2003
tositumomab (Bexxar)
First NDA Approval
2003
tositumomab (Bexxar)
Last Known Activity
2004

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Corixa Corporation

Active Ingredients

Marketed Drugs (1)

Key: Corixa (0) Acquired (1)

tositumomab (Bexxar) (2003 NDA)

Drugs in Phase 3 Trials (2)

Key: Corixa (1) Acquired (1)

rituximab (rituxan) (1 trial)

tositumomab (Bexxar) (3 trials)

Drugs in Phase 2 Trials (8)

acetaminophen (tylenol) (1 trial)

anti-b1 antibody (6 trials)

cyclophosphamide (cytoxan) (1 trial)

diphenhydramine (benadryl) (1 trial)

doxorubicin (Doxil) (1 trial)

potassium iodide (thyro-block) (1 trial)

prednisone (meticorten) (1 trial)

vincristine (oncovin) (1 trial)

Drugs in Phase 1 Trials (3)

ad/l523s (1 trial)

gsk692342 (1 trial)

pvax/l523s (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 1)

Leukemia (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 1)

Lung Neoplasms (Phase 1)

Lymphoma (Phase 3)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 3)

Tuberculosis (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 13